EP0773716A4 - Traitement de solutions de globules rouges par des agents antiviraux - Google Patents

Traitement de solutions de globules rouges par des agents antiviraux

Info

Publication number
EP0773716A4
EP0773716A4 EP96918369A EP96918369A EP0773716A4 EP 0773716 A4 EP0773716 A4 EP 0773716A4 EP 96918369 A EP96918369 A EP 96918369A EP 96918369 A EP96918369 A EP 96918369A EP 0773716 A4 EP0773716 A4 EP 0773716A4
Authority
EP
European Patent Office
Prior art keywords
treatment
antiviral agents
red cell
cell solutions
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918369A
Other languages
German (de)
English (en)
Other versions
EP0773716A1 (fr
Inventor
David Cook
Susan Wollowitz
Aileen Nerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/476,842 external-priority patent/US6143490A/en
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of EP0773716A1 publication Critical patent/EP0773716A1/fr
Publication of EP0773716A4 publication Critical patent/EP0773716A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96918369A 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux Withdrawn EP0773716A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US486821 1995-06-07
US476842 1995-06-07
US08/476,842 US6143490A (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
US08/486,821 US6171777B1 (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
PCT/US1996/009616 WO1996039818A1 (fr) 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux

Publications (2)

Publication Number Publication Date
EP0773716A1 EP0773716A1 (fr) 1997-05-21
EP0773716A4 true EP0773716A4 (fr) 1999-08-04

Family

ID=27045311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918369A Withdrawn EP0773716A4 (fr) 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux

Country Status (4)

Country Link
EP (1) EP0773716A4 (fr)
AU (1) AU722811B2 (fr)
CA (1) CA2199731A1 (fr)
WO (1) WO1996039818A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
AU773836B2 (en) * 1997-01-06 2004-06-10 Cerus Corporation Methods and devices for the reduction of small organic compounds from blood products
CA2276532C (fr) * 1997-01-06 2008-06-17 Cerus Corporation Composes frangibles pour inactivation pathogene
EP1364944A1 (fr) * 1997-01-06 2003-11-26 Cerus Corporation Composés frangibles pour inactivation pathogène
CA2276747C (fr) * 1997-01-06 2004-04-13 Cerus Corporation Procedes et dispositifs permettant de reduire de petits composes organiques presents dans des produits sanguins
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US7611831B2 (en) 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
JP2003523777A (ja) * 1998-01-06 2003-08-12 シーラス コーポレイション 細胞を含む生物学的組成物からの化合物の減少のためのバッチデバイスおよびその使用方法
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
WO1999063981A2 (fr) * 1998-06-11 1999-12-16 Cerus Corporation Inhibition de la proliferation des cellules musculaires lisses arterielles
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (fr) 2003-02-06 2004-10-07 Cerus Corporation Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants
EP1687275A4 (fr) * 2003-11-21 2009-01-14 Merck & Co Inc Composes de pyridin-4-ylamine convenant pour le traitement de la douleur neuropathique
CN101094692A (zh) 2004-10-29 2007-12-26 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法
SG189745A1 (en) 2008-04-09 2013-05-31 Cerus Corp Improved quenching methods for red blood cell pathogen inactivation
CN101857598B (zh) * 2010-06-25 2012-11-28 西安交通大学 一种具有降高血压活性的呋喃香豆素类化合物及其制备方法
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
WO2016210374A1 (fr) 2015-06-26 2016-12-29 Cerus Corporation Compositions de cryoprécipités et leurs procédés de préparation
EP3364986B1 (fr) 2015-10-23 2023-12-13 Cerus Corporation Plasma cryogénique inactivé par des agents pathogènes et procédé pour son utilisation
EA201991506A1 (ru) 2016-12-23 2020-01-23 Сирус Корпорейшн Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CN110573169B (zh) 2017-03-03 2024-10-01 塞鲁斯公司 制备病原体灭活的血小板组合物的试剂盒和方法
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的系统和方法
CN114173842A (zh) 2019-06-22 2022-03-11 塞鲁斯公司 生物流体处理系统
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
WO2020264421A1 (fr) 2019-06-28 2020-12-30 Cerus Corporation Système et procédés permettant de mettre en œuvre un dispositif de traitement de fluide biologique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (fr) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. Système de traitement du sang en dehors du corps
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182750A (en) * 1977-04-21 1980-01-08 Sullivan Thomas E Bloodcompatible functional polymers
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
ES2337852T3 (es) * 1995-06-07 2010-04-29 Cerus Corporation Metodos y dispositivos para la eliminacion de psoralenos de productos sanguineos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (fr) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. Système de traitement du sang en dehors du corps
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RYTIR V ET AL: "Effect of certain compounds during elimination of plasmids in Escherichia coli", FOLIA MICROBIOLOGICA, vol. 20, no. 1, 1975, Prague, Czech., pages 17 - 23, XP002101363 *
See also references of WO9639818A1 *

Also Published As

Publication number Publication date
AU722811B2 (en) 2000-08-10
AU6104996A (en) 1996-12-30
WO1996039818A1 (fr) 1996-12-19
EP0773716A1 (fr) 1997-05-21
CA2199731A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
OA08617A (fr) Inhibiteurs de métalloendopeptidase neutre dans le traitement de l'hypertention.
FR2582947B1 (fr) Dispositif de traitement par hyperthermie
EP0667769A4 (fr) Utilisation de composes specifiques alpha-1c dans le traitement de l'hyperplasie benigne de la prostate.
EP0831836A4 (fr) Intercepteurs catalytiques synthetiques de radicaux libres s'utilisant comme antioxydants dans la prevention et le traitement de maladies
EP0925046A4 (fr) Formulations topiques et methodes de traitement des douleurs hemorroidales
MA19428A1 (fr) Gilet orthopedique de soutien et de contention dans le traitement des traumatises et des operes de l'epaule, de la ceinture scapulaire et du membre superieur
FR2586490B1 (fr) Unite de traitement d'instruction de branchement
EP0758226A4 (fr) Globules rouges artificiels
FR2643557B1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
BR9305310A (pt) Conjunto de came e conjunto de came "S"
GB9223552D0 (en) Improvements in or relating to the treatment of effluents
EP0861082A4 (fr) Traitement de l'insuffisance de la membrane tissulaire
FR2595681B1 (fr) Traitement de l'eau et analyse des sols
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
EP0591408A4 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0752880A4 (fr) Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
MC2246A1 (fr) Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
EP0755255A4 (fr) Traitement de la toxoplasmose
MA20786A1 (fr) Traitement de liquide radio-actif
EP0800396A4 (fr) Traitement d'etats d'hyperandrogenie
FR2630099B1 (fr) Procede de traitement et de purification d'eaux
GB9216506D0 (en) Improvements in or relating to the treatment of sickle cell disease
EP0840605A4 (fr) Composes utiles dans le traitement des neurofibromatoses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19970304

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61L 2/00 A, 6A 61L 2/18 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CERUS CORPORATION

17Q First examination report despatched

Effective date: 20010319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001